Key result
Oxidized LDL and related antibodies show promise as biomarkers and therapeutic targets in cardiovascular disease.
Why the study?
Better identification of individuals at risk of cardiovascular disease and atherosclerotic plaques with unfavorable characteristics is needed through novel biomarkers and therapeutic targets.
Answers are grounded in this paper and cite their sources.
This review highlights the emerging role of oxidized LDL and its antibodies as potential biomarkers and therapeutic or imaging targets for cardiovascular disease.
We provide an up-to-date overview of current topics surrounding oxidized low-density lipoprotein (oxLDL) and its related antibodies in the quest to better identify the individuals at risk of cardiovascular disease and atherosclerotic plaques with unfavorable characteristics. We discuss the potential of oxLDL and anti-oxLDL antibodies as serum biomarkers of cardiovascular disease and emerging studies examining the targeting of arterial oxLDL for imaging and therapeutic delivery.
No takes yet. Share an insight, caveat, or question.
Hartley et al. (2018) conducted a review in Cardiovascular disease and atherosclerosis. Oxidized LDL and anti-oxidized LDL antibodies was evaluated. Oxidized LDL and anti-oxidized LDL antibodies show potential as serum biomarkers and emerging targets for imaging and therapeutic delivery in cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: